¿ìè¶ÌÊÓƵ

American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Ga; 2016.

American Cancer Society. Cancer Facts & Figures 2017. Atlanta, Ga; 2017.

Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.

Maity A, Pruitt AA, Judy KD, et al. Cancer of the central nervous system. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1075-1136.

Mehta MP, Vogelbaum M, Chang S, Patel N. Neoplasms of the central nervous system. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1700-1749.

National Cancer Institute Physician Data Query (PDQ). Adult Brain Tumors Treatment. 2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/adultbrain/healthprofessional on December 18, 2013.

National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. V.2.2013. Accessed at www.nccn.org/professionals/physician_gls/pdf/cns.pdf on December 18, 2013.

Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA. 2013;310:1842−1850.

Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15 Suppl 2:ii1−56.

Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62:125–135.

Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:4722−4729.